CD8A and neoplasm: However, after stopping osimertinib injection of IVT4 not only inhibited outgrowth of the tumor compared to the non-specific control IVT-GAC but led to a further reduction in tumor volume and a lower rate of TIM3+/PD-1+CD69− CD8 cells with osi pre-treatment (Fig. 5f, g, Supplementary Fig. 8d, e).